LONG-ACTING INJECTABLE BROMOCRIPTINE (PARLODEL LAR) IN THE CHRONIC TREATMENT OF PROLACTIN-SECRETING MACROADENOMAS

Página do item simplificado
dc.contributor.authorLengyel, Ana Maria Judith [UNIFESP]
dc.contributor.authorMussio, Wania [UNIFESP]
dc.contributor.authorImamura, Paulo Mitsuru [UNIFESP]
dc.contributor.authorVieira, Jose Gilberto Henriques [UNIFESP]
dc.contributor.authorLancranjan, Ioana
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionSANDOZ PHARMA LTD
dc.date.accessioned2018-06-15T17:30:17Z
dc.date.available2018-06-15T17:30:17Z
dc.date.issued1993-05-01
dc.description.abstractObjective: To evaluate the efficacy and tolerability of Parlodel LAR (Sandoz, Basel, Switzerland), a long-acting injectable bromocriptine, in PRL-secreting macroadenomas.Design: Eleven patients with macroprolactinomas were studied in an academic environment in an open and prospective protocol. Ten patients were followed for 6 months and 8 for 1 year. Fifty to 200 mg IM of Parlodel LAR were administered every 28 days.Results: At the end of the 1st month, 64% of the patients had PRL suppression of >75% of baseline values. After 1 year, 88% of the cases had PRL suppression of >90%. Persistent PRL normalization was seen in three cases. Tumor shrinkage was seen in 64% of the patients on day 5, in 73% on day 28, and in 90% after 6 months of treatment. Early visual field improvement was seen in 83% of the cases. All patients had improvement of clinical symptoms.Conclusion: Parlodel LAR is well tolerated and very effective in the long-term treatment of patients with PRL-secreting macroadenomas.en
dc.description.affiliationESCOLA PAULISTA MED SCH,DIV OPHTHALMOL,BR-04034 SAO PAULO,BRAZIL
dc.description.affiliationSANDOZ PHARMA LTD,DEPT NEUROENDOCRINOL,BASEL,SWITZERLAND
dc.description.affiliationUnifespESCOLA PAULISTA MED SCH,DIV OPHTHALMOL,BR-04034 SAO PAULO,BRAZIL
dc.description.sourceWeb of Science
dc.format.extent980-987
dc.identifierhttp://www.fertstert.org/article/S0015-0282(16)55914-7/pdf
dc.identifier.citationFertility And Sterility. Birmingham: Amer Soc Reproductive Medicine, v. 59, n. 5, p. 980-987, 1993.
dc.identifier.doi10.1016/S0015-0282(16)55914-7
dc.identifier.issn0015-0282
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/43681
dc.identifier.wosWOS:A1993LB26900007
dc.language.isoeng
dc.publisherAmer Soc Reproductive Medicine
dc.relation.ispartofFertility And Sterility
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPARLODEL LARen
dc.subjectMACROPROLACTINOMASen
dc.subjectINJECTABLE BROMOCRIPTINEen
dc.subjectPRL-SECRETING MACROADENOMASen
dc.subjectCHRONIC TREATMENTen
dc.titleLONG-ACTING INJECTABLE BROMOCRIPTINE (PARLODEL LAR) IN THE CHRONIC TREATMENT OF PROLACTIN-SECRETING MACROADENOMASen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos